Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:insulin
gptkb:lixisenatide |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2016 |
| gptkbp:ATCCode |
A10AE54
|
| gptkbp:brand |
gptkb:insulin_glargine_and_lixisenatide
|
| gptkbp:contraindication |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:form |
solution for injection
pre-filled pen |
| https://www.w3.org/2000/01/rdf-schema#label |
Soliqua
|
| gptkbp:indication |
improving glycemic control
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:pregnancyCategory |
C
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
nausea diarrhea headache upper respiratory tract infection |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:insulin
gptkb:赛诺菲 |
| gptkbp:bfsLayer |
6
|